We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Guidance on Unsanitary Conditions at Compounding Facilities Gets Mixed Reviews

Guidance on Unsanitary Conditions at Compounding Facilities Gets Mixed Reviews

November 4, 2016

The FDA draft guidance on unsanitary conditions at drug compounding facilities got mixed reviews in comments on the draft.

One commenter questioned the need for the guidance, calling it an overreaction to the event that led to the guidance, a 2012 meningitis outbreak. The comment pointed to evidence that between 2000 and 2012 only 20 adverse events were linked to compounders that were not related to the New England Compounding Center, the source facility of the 2012 outbreak.

A second commenter said the guidance ignores other significant issues.

“The emphasis that this guidance document gives to the appearance of unsanitary conditions linked to potential microbial contamination at sterile compounding facilities downplays risks associated with bacterial endotoxin, super and sub potent preparations, chemical and physical contamination and use of inappropriate ingredients,” the commenter said.

The third and final comment said the guidance does not address the use of sterile versus non-sterile clothing except for gloves. Hoods, goggles, face masks, shoe covers and other items are not mentioned, and at a minimum, sterile sleeves should be addressed in the guidance, the commenter said.

The comments could be an indication that many in the compounding industry, especially in the U.S., aren’t worried about sanitation issues due to standards that are already in place and enforced. When it comes to overseas facilities, things could be different. 

The FDA does not inspect the vast majority of compounding facilities in the U.S. because they generally do not register with FDA unless they elect to become outsourcing facilities.

Therefore, FDA is often not aware of these facilities and potential problems with their drug products, or conditions and practices, unless it receives a complaint such as a report of a serious adverse event or visible contamination.

The guidance will assist compounding facilities in identifying insanitary conditions so that they can implement appropriate corrective actions. It also is expected to help state regulatory agencies in understanding some examples of what FDA considers insanitary conditions.

Parenteral drug products have been under a barrage of GMP-related problems of late. From cloudy vials to glass shards in syringes to microbial contamination, parenteral manufacturing has taken a hit. Be ready by brushing up your knowledge on: Avoiding Problems with FDA in Manufacturing Parenteral Products.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WHO

    J&J Seeks WHO Emergency Use Listing for COVID-19 Vaccine

  • Partner Up, blocks

    Becton Dickinson, Scanwell Health Partnering on COVID-19 Rapid Home Test

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing